• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals reported a strong lift in revenue and earnings for the 2020 financial year following sales growth and cost control in its diversified Australasian medicines business and growing international sales of its patented Maxigesic pain relief drug.

    To view the announcement please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Analyst Coverage

Firm Analyst Contact Details Reports
Jarden/Credit Suisse Jack Crowley
Director, Equity Research
Jack.Crowley@jarden.co.nz
Forsyth Barr Chelsea Leadbetter
CFA
chelsea.leadbetter@forsythbarr.co.nz
Edison Group Maxim Jacobs mjacobs@edisongroup.comOpens in new window

AFT is followed by the analysts listed above. Any opinions, forecasts and estimates regarding AFT’s performance made by these analysts are theirs alone and are made independently of AFT. They do not represent opinions, forecasts, estimates or predictions of AFT, its directors or its management.   AFT does not by its reference to the analyst details and links to publicly available reports above imply its endorsement of or agreement with any information, conclusion or recommendations made by an analyst.  AFT does not provide any assurance that information stated in any analyst report is correct.